T-cell vaccination in multiple sclerosis: Immunoregulatory mechanism and prospects for therapy

Critical Reviews in Immunology

Volumn 21, Issue 1-3, 2001, Pages 41-55

  Zhang, J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Multiple sclerosis; Myelin reactive T cells; T cell vaccination

Indexed keywords

MYELIN BASIC PROTEIN; PEPTIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR;

ANTIBODY RESPONSE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; HUMORAL IMMUNITY; IMMUNOREGULATION; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE; TH2 CELL; VACCINATION;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; AUTOANTIGENS; CLINICAL TRIALS; HUMANS; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; MYELIN SHEATH; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TH2 CELLS; VACCINATION;

EID: 0034788642     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (63)

1. Vaccination against autoimmune encephalomyelitis with T lymphocyte line cells reactive against myelin basic protein
2. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system
3. A new family of transcripts of the myelin basic protein gene: Expression in brain and immune system
4. The human myelin basic protein gene is included within a 179-kilobase transcription unit: Expression in the immune and central nervous systems
5. Human T lymphocytes specific for the immunodominant 83-99 epitope of myelin basic protein: Recognition of golli MBP HOG 7
6. Response of human T lymphocyte lines to myelin basic protein: Association of dominant epitopes with HLA class II restriction molecules
7. Preferential peptide and HLA restriction of MBP specific T cell clones derived from MS patients
8. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: Precursor frequency, fine specificity, and cytotoxicity
9. T cell recognition of an immunodominant MBP epitope in multiple sclerosis
10. Myelin autoreactivity in multiple sclerosis: Recognition of MBP in the context of HLA-DR2 products by T lymphocytes of multiple sclerosis patients and healthy donors
11. A MBP peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis
12. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans
13. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate
14. Reactivity to myelin antigens in multiple sclerosis
15. Two mechanisms of antigen-specific apoptosis of myelin basic protein (MBP)-specific T lymphocytes derived from patients with multiple sclerosis and normal individuals
16. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis
17. T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects
18. T cells responsive to myelin basic protein in patients with multiple sclerosis
19. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis
20. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis
21. T cell reactivity to myelin antigens and their structural and functional properties at different clinical stages of multiple sclerosis
22. TCR usage in human and experimental demyelinating disease
23. Clonal expansion of myelin basic protein-reactive T cells in patients with multiple sclerosis: Restricted T cell receptor V gene rearrangements and CDR3 sequence
24. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide
25. Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis
26. An αβ T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex
27. Restricted TCR V-alpha gene rearrangement in T cells recognizing an immunodominant peptide of myelin basic protein in DR2 patients with multiple sclerosis
28. β usage to immunodominant regions of myelin basic protein
29. Selection for T cell receptor V-D-J gene rearrangements with specificity for a myelin basic protein peptide in the brain lesions of multiple sclerosis
30. A common TCR sequence motif shared by myelin basic protein-reactive T cells in patients with multiple sclerosis
31. Therapeutic vaccination against adjuvant arthritis using autoimmune T cells treated with hydrostatic pressure
32. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein
33. Control of experimental autoimmune uveoretinitis by low dose T cell vaccination
34. T cell vaccination in multiple sclerosis: A preliminary report
35. MHC restricted clonotypic depletion of human myelin basic protein-reactive T cells by T cell vaccination
36. T cell vaccination trial in multiple sclerosis
37. T cell vaccination in human autoimmune diseases: From laboratory to clinic
38. Depletion of myelin basic protein autoreactive T cells by T cell vaccination: Clinical trial in multiple sclerosis
39. T cell vaccination in multiple sclerosis: Results of a preliminary clinical trial
40. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
41. Placebo-controlled multicentre randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
42. In vivo donotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination
43. Spontaneous regression of primary autoreactiviry during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis
44. Natural Id-anti-Id networks and the immunological homunculus
45. + cells recognizing epitopes of the T cell receptor β chain from a myelin basic protein-specific T cell clone
46. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis
47. T cell vaccination in secondary progressive multiple sclerosis
48. Preferential recognition of hypervariable region sequence by anti-idiotypic T cells induced by T cell vaccination in patients with multiple sclerosis
49. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses
50. Mechanism of MHC class I-restricted antigen processing
51. CDR1 T-cell receptor beta-chain peptide induce major histocompatibility complex class II restricted T-T cell interactions
52. + T cells in recovery from antigen-induced autoimmune disease
53. Reactivity and regulatory properties of anti-idiotypic antibodies induced by T cell vaccination in patients with multiple sclerosis
54. Possible mechanism of immunotherapy for maintaining pregnancy in recurrent spontaneous aborters: Analysis of anti-idiotypic antibodies directed against autologous T cell receptor
55. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis
56. Spreading of T cell autoimmunity to cryptic determinants of an autoantigen
57. IL-2 and TNF receptors as targets of regulatory T-T interactions: Isolation and characterization of cytokine receptor-reactive T cell lines in the Lewis rat
58. Myelin reactive T cells after T cell vaccination in multiple sclerosis: Cytokine profile and depletion by additional immunizations
59. Transfer of multiple sclerosis into severe combined immunodeficiency mice by mononuclear cells from cerebrospinal fluid of the patients
60. Demyelination in severe combined immunodeficient mice by intracisternal injection of cerebrospinal fluid cells from patients with multiple sclerosis: Neuropathological investigation
61. Immunization with a synthetic T cell receptor V-region peptide protects against experimental autoimmmune encephalomyelitis
62. Vaccination against experimental encephalomyelitis with T cell receptor peptides
63. Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial